Robert Buckley Sells 9,957 Shares of Novanta (NASDAQ:NOVT) Stock

Novanta Inc. (NASDAQ:NOVT) CFO Robert Buckley sold 9,957 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $116.77, for a total transaction of $1,162,678.89. Following the completion of the transaction, the chief financial officer owned 96,616 shares in the company, valued at $11,281,850.32. This trade represents a 9.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Robert Buckley also recently made the following trade(s):

• On Friday, February 20th, Robert Buckley sold 1,423 shares of Novanta stock. The shares were sold at an average price of $140.88, for a total value of $200,472.24.
• On Wednesday, January 21st, Robert Buckley sold 1,423 shares of Novanta stock. The shares were sold at an average price of $140.14, for a total value of $199,419.22.

Novanta Price Performance

NASDAQ NOVT opened at $118.58 on Friday. The company has a current ratio of 3.69, a quick ratio of 2.80 and a debt-to-equity ratio of 0.16. Novanta Inc. has a 12 month low of $98.27 and a 12 month high of $149.95. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of 81.22 and a beta of 1.61. The company’s 50 day moving average is $135.04 and its two-hundred day moving average is $121.19.

Novanta (NASDAQ:NOVT) last announced its quarterly earnings data on Monday, February 23rd. The technology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novanta had a net margin of 5.49% and a return on equity of 13.12%. The firm had revenue of $258.35 million for the quarter, compared to the consensus estimate of $260.72 million. During the same period last year, the firm earned $0.76 EPS. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. As a group, research analysts anticipate that Novanta Inc. will post 3.03 earnings per share for the current year.

Institutional Trading of Novanta

Hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. increased its position in Novanta by 15.4% in the third quarter. Envestnet Asset Management Inc. now owns 81,691 shares of the technology company’s stock worth $8,181,000 after purchasing an additional 10,896 shares during the last quarter. Bessemer Group Inc. lifted its position in Novanta by 24.8% during the third quarter. Bessemer Group Inc. now owns 222,391 shares of the technology company’s stock valued at $22,272,000 after purchasing an additional 44,252 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in Novanta by 22.1% during the third quarter. Exchange Traded Concepts LLC now owns 178,375 shares of the technology company’s stock valued at $17,864,000 after purchasing an additional 32,278 shares during the last quarter. Atika Capital Management LLC purchased a new position in shares of Novanta in the 2nd quarter worth $1,367,000. Finally, Congress Asset Management Co. purchased a new position in shares of Novanta in the 3rd quarter worth $59,153,000. 98.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NOVT. Zacks Research raised Novanta from a “strong sell” rating to a “hold” rating in a report on Friday, January 16th. Weiss Ratings upgraded shares of Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 20th. Finally, Robert W. Baird set a $150.00 target price on shares of Novanta in a research report on Wednesday, February 25th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $150.00.

About Novanta

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.